Enterprise
Pricing
Explore API
Get a demo
Get started
Now livetag icon
Ad Intelligence Presents: Ads in ChatGPT & Google. Download the reportbanner icon
Formycon

April 2026

Formycon Market Share Analysis for April 2026

Die Formycon AG und die Bioeq AG geben bekannt, dass die U.S. Food and Drug Administration die Zulassung für Nufymco® (Ranibizumab-leyk), einem austauschbaren Biosimilar zu Lucentis®, erteilt hat.
Health > Biotechnology and Pharmaceuticals
Domainformycon.com
Year Founded2012
Employees201 - 500
Annual Revenue$50M - $75M
HQ:Germany, Planegg
formycon.com
Formycon
Formycon (including company regionals)
  • formycon.com
    formycon.com
See more website traffic and engagement information

Formycon Revenue up to April 2026 is 50M - 75M

revenue generated by Formycon top domains

Formycon top domains revenue over 3 years

Revenue for Formycon top domains

formycon.comformycon.com50M - 75M
See more with Sales Intelligence

Total visits to Formycon's top domains

Understand Formycon market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown
formycon.comformycon.com5.6K
See more with Sales Intelligence

Avg. visit duration in Formycon's top domains

Analyze Formycon engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown
formycon.comformycon.com00:01:07
See more with Sales Intelligence

Avg. pageviews on Formycon's top domains

See how Formycon keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown
formycon.comformycon.com3.08
See more with Sales Intelligence

Want to gain deeper traffic insights?

Filter 20.3M+ online businesses. Discover new leads when their traffic spikes, when they start or stop using technologies, or when they get positive press.

Formycon top competitors by domain

Looks like there’s not enough data here

No Data to Display

Benchmark Your Digital Performance

Identify high-value opportunities, track your performance, and win your market.

Top technologies used by Formycon

These are the website technologies, by industry, used by Formycon top domains

Widget (4)

Twemoji

Twemoji

See all

Advertising (3)

DoubleClick

DoubleClick

See all

Conversion & Analytics (2)

Matomo (Previously Piwik)

Matomo (Previously Piwik)

See all

Mobile (2)

Meta Viewport

Meta Viewport

See all

More Technologies

8

See all

Ready to discover high quality prospects?

Identify what technologies a website uses to craft the perfect sales pitch, and shorten the sales cycle with the Similarweb Sales Intelligence Solution.

News & Signals from Formycon

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsFormycon AG launched Eylea[1] 2mg biosimilar FYB203 on May 15th '26.Formycon AG and its licensing partner Klinge Biopharma GmbH ("Klinge") jointly announce the launch of the Eylea[1] 2mg biosimilar FYB203 in the European Union.
May 19, 2026Read More
NewsFormycon AG is developing high-quality biosimilars targeting ophthalmology, immunology, and chronic diseases.Formycon continues to develop high-quality biosimilars targeting ophthalmology, immunology, and chronic diseases, covering the full value chain from technical development through Phase III trials and regulatory preparation.
May 13, 2026Read More

See all Formycon signals

Focus your sales teams on the most promising opportunities. By prioritizing opportunities and engaging at the right time, you can optimize efforts and close more deals.